60. Aplastic anemia Clinical trials / Disease details
Clinical trials : 245 / Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00960050 (ClinicalTrials.gov) | June 2009 | 14/8/2009 | Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone | Dapsone Induced Methemoglobinemia Study (DIMS) | Leukemia;Lymphoma;Methemoglobinemia;Nonmalignant Neoplasm | Genetic: polymorphism analysis;Other: laboratory biomarker analysis;Other: medical chart review;Procedure: assessment of therapy complications | Vanderbilt-Ingram Cancer Center | National Cancer Institute (NCI) | Active, not recruiting | N/A | 22 Years | Both | 173 | United States | |
| 2 | NCT00993694 (ClinicalTrials.gov) | January 2009 | 9/10/2009 | Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone | Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia | Chronic Myeloproliferative Disorders;Leukemia;Lymphoma;Lymphoproliferative Disorder;Methemoglobinemia;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Neoplasms;Nonmalignant Neoplasm | Drug: chemotherapy;Drug: dapsone;Other: medical chart review;Procedure: assessment of therapy complications | Vanderbilt University | National Cancer Institute (NCI) | Completed | N/A | 18 Years | All | 41 | N/A | United States |